Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open‐label, cross‐over study using continuous glucose monitoring profiles
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Aims/Introduction: Compared with glargine 100 U/mL (Gla100), glargine 300 U/mL (Gla300) and degludec (Deg) – the ultralong‐acting insulins – reportedly have more stable effects and reduce the risk of hypoglycemia. Currently, they are considered to be the most useful basal insulins. The present study aimed to compare the efficacy and safety of Gla300 and Deg on glycemic control using continuous glucose monitoring. Materials and Methods: In this single‐center, open‐label, parallel‐group, two‐period, cross‐over study, 30 patients with type 2 diabetes were randomized to once‐daily Gla300 followed by Deg with the same units (n = 15) or vice versa (n = 15). The primary end‐points of this study were the mean percentage of time within the target glucose range of 70–180 mg/dL as efficacy and hypoglycemia of <70 mg/dL as safety indicators, as measured using continuous glucose monitoring during each treatment period. Results: The mean percentage of time within the target glucose range was not different between Gla300 and Deg (77.8 ± 19.2 vs 76.9 ± 18.3%, P = 0.848). However, the mean percentage of time of hypoglycemia with Gla300 was significantly lower than that of Deg (1.3 ± 2.7 vs 5.5 ± 6.4%, P = 0.002). In the secondary safety end‐points, the mean percentage of time of severe hypoglycemia (<54 mg/dL) or nocturnal hypoglycemia with Gla300 was also significantly lower than that of Deg. Conclusions: The present study showed the comparable efficacy of Gla300 and Deg on glycemic control; however, the risk of hypoglycemia was markedly lower for Gla300 than for Deg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2. Classification and Diagnosis of Diabetes
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s005 · Cited by 1,603
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 h in Patients With NIDDM
Reaven, G. M., Hollenbeck, C., Jeng, C.-Y., Wu, M. S., & Chen, Y.-D. I. (1988) · Diabetes · doi:10.2337/diab.37.8.1020 · Cited by 753
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Goto, A., Arah, O. A., Goto, M., Terauchi, Y., & Noda, M. (2013) · BMJ · doi:10.1136/bmj.f4533 · Cited by 492
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Glucose Variability; Does It Matter?
Siegelaar, S. E., Holleman, F., Hoekstra, J. B. L., & DeVries, J. H. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0021 · Cited by 409
Ratner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-0990 · Cited by 274
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248
Meneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1668 · Cited by 226
Lane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA · doi:10.1001/jama.2017.7115 · Cited by 206
Sleep restriction increases free fatty acids in healthy men
Broussard, J. L., Chapotot, F., Abraham, V., Day, A., Delebecque, F., Whitmore, H. R., & Tasali, E. (2015) · Diabetologia · doi:10.1007/s00125-015-3500-4 · Cited by 156
The FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135
Cited by
Miura, H., Sakaguchi, K., Otowa‐Suematsu, N., Yamada, T., So, A., Komada, H., Okada, Y., Hirota, Y., Tamori, Y., & Ogawa, W. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14161 · Cited by 25
Battelino, T., Bosnyak, Z., Danne, T., Mukherjee, B., Edelman, S., Pilorget, V., Choudhary, P., Renard, E., & Bergenstal, R. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00781-6 · Cited by 23
Cheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
Battelino, T., Edelman, S. V., Nishimura, R., & Bergenstal, R. M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0180 · Cited by 13
Kawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Self-citation
Metadata
- Authors
- Kawaguchi, Y., Sawa, J., Sakuma, N., & Kumeda, Y.
- Venue
- Journal of Diabetes Investigation
- Publisher
- Wiley
- Published
- 2018-07-28
- Volume
- 10
- Issue
- 2
- Pages
- 343-351
- ISSN
- 2040-1116 (ISSN-L)
- 2040-1124
- OpenAlex
- W2811311343
- Cited by
- 40
- References
- 18
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.